Our anti-BTLA modulator antibody, known as ANB032, is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. Mutations in the BTLA signaling pathway are associated with human inflammatory disease and we believe ANB032 silences pro-inflammatory signaling by modulating BTLA binding to HVEM. We presented preclinical data regarding ANB032 at the Federation of Clinical Immunology Societies meeting in October 2020.

We achieved first-in-human dosing of ANB032 upon initiation of a healthy volunteer Phase 1 trial in the first quarter of 2021, under an Australian Clinical Trial Notification (CTN), and anticipate top-line data from this trial during the first half of 2022.

To access scientific publications on this topic, please click here.